Verbeek, M. W. C., Buracchi, C., Laqua, A., Nierkens, S., Sedek, L., Flores-Montero, J., . . . Velden, V. H. J. v. d. (2022). Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies — a EuroFlow study.
Citación estilo ChicagoVerbeek, Martijn W. C., et al. Flow Cytometric Minimal Residual Disease Assessment in B-cell Precursor Acute Lymphoblastic Leukaemia Patients Treated With CD19-targeted Therapies — a EuroFlow Study. 2022.
Cita MLAVerbeek, Martijn W. C., et al. Flow Cytometric Minimal Residual Disease Assessment in B-cell Precursor Acute Lymphoblastic Leukaemia Patients Treated With CD19-targeted Therapies — a EuroFlow Study. 2022.
Precaución: Estas citas no son 100% exactas.